Genomic amplification of chromosome 7 in the Doxorubicin resistant K562 cell line

Area of Science:

• Molecular Biology
• Cancer Research
• Genomics

Background:

• Multi-drug resistance (MDR) is a significant challenge in cancer therapy.
• ABCB1 (ATP-binding cassette sub-family B member 1) overexpression is a common mechanism for MDR in cancers, including acute myeloid leukemia (AML).
• Understanding the mechanisms of ABCB1 upregulation is crucial for overcoming treatment resistance.

Purpose of the Study:

• To investigate the role of genomic amplification in the 7q11.21-7q22.1 region on ABCB1 overexpression in an acute myeloid leukemia (AML) cell line.
• To establish a doxorubicin (Dox)-resistant K562 cell line model to study MDR acquisition.

Main Methods:

• Development of a doxorubicin (Dox)-resistant K562 cell line exhibiting a multi-drug resistance (MDR) phenotype.
• Characterization of chromosomal changes using array-based comparative genomic hybridization (aCGH) comparing the resistant cell line to the parental K562 cells.
• Quantification of ABCB1 mRNA levels.

Main Results:

• Significant genomic gains were identified in the 7q11.21-7q22.1 chromosomal region in the Dox-selected K562 cell line.
• The identified amplicon encompasses the ABCB1 gene locus at 7q21.1, showing a copy number gain greater than 4.
• ABCB1 mRNA levels were found to be upregulated by 54-fold in the resistant cell line.

Conclusions:

• Genomic amplification of the chromosome 7 region containing the ABCB1 gene is a key mechanism underlying the development of multi-drug resistance (MDR) in this K562/Dox cell line model.
• This finding highlights the importance of chromosomal alterations in the acquisition of MDR in leukemia.
• Targeting ABCB1 or the amplification event could be a potential strategy to overcome MDR in AML.